Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2007 01:33 ET | Source: Orion

532.051 Orionin A-osaketta muunnettu B-osakkeiksi

532.051 Orionin A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla 532.051 A-osaketta on muunnettu 532.051 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin...
May 21, 2007 01:33 ET | Source: Orion Oyj

532,051 Orion A-shares converted into B-shares

532,051 Orion A-shares converted into B-shares In accordance with Section 3 of the Bylaws of Orion Corporation, 532,051 A-shares have been converted into 532,051 B-shares. The...
May 21, 2007 01:32 ET | Source: Orion Oyj

532.051 Orionin A-osaketta muunnettu B-osakkeiksi

532.051 Orionin A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla 532.051 A-osaketta on muunnettu 532.051 B-osakkeeksi. Muuntaminen on merkitty...
May 21, 2007 01:30 ET | Source: Unibail-Rodamco-Westfield SE

Unibail makes a recommended exchange offer for all outstanding shares of Rodamco Europe

The Exchange Ratio (as defined below) is 0.5223 of a Unibail share with a nominal value of five euros (EUR 5) (a "Unibail Share") to be exchanged for each Rodamco Share (the "Share Offer"). This...
May 21, 2007 01:15 ET | Source: Novartis Pharma AG

Exforge® helps vast majority of patients effectively control their blood pressure after failing on other medicines, according to new clinical data

Nine out of 10 non-diabetic patients treated with Exforge achieved recommended blood pressure goals[1] Additional average decrease of 20 mmHg in systolic blood pressure observed in patients...
May 21, 2007 01:15 ET | Source: Novartis Pharma AG

Single-tablet combination of Tekturna® and diuretic, an important new option for people with high blood pressure, submitted for US approval

Tekturna, approved in the US in March 2007, represents the first new type of medicine for treating high blood pressure in more than a decade New data show Tekturna, when used alone or in...
May 21, 2007 01:15 ET | Source: Novartis Pharma AG

Novartis defends its intellectual property rights as US court issues order prohibiting Teva from selling a generic version of Lotrel

Novartis has a valid US patent for Lotrel - a single-tablet combination therapy for high blood pressure - until December 2017 Temporary restraining order granted on May 19 after Teva...
May 21, 2007 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Wirksamkeit und Nebenwirkungsprofil von Basileas Alitretinoin zur Behandlung des schweren refraktären chronischen Handekzems durch die am Europäischen Dermatologie Kongress vorgestellten Daten bestätigt

Basel, Schweiz, 21. Mai, 2007 - Ergebnisse aus klinischen Phase-III-Studien sowie weitere pharmakologische Daten wurden am 16. Kongress der "European Academy of Dermatology and Venereology" (EADV)...
May 21, 2007 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

Basel, Switzerland, May 21, 2007 - Results from phase III clinical trials and further human pharmacology studies were presented at the 16th Congress of the European Academy of Dermatology and...
May 21, 2007 01:00 ET | Source: Ensurge Micropower ASA

OTB Engineering and Thin Film Electronics sign Development Agreement to jointly develop inkjet in-line printing solutions using OTB's printing technology to enable industrial manufacturing of Thinfilm's memory devices

Eindhoven, The Netherlands - May 21, 2007 - OTB Engineering ("OTB") of Eindhoven, The Netherlands, a leading company in the design, development, engineering and manufacturing of production...

1 ...301756 301757 301758 ...316329